| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
45 |
| Revenues (TTM) (Millions $) |
8 |
| Net Income (TTM) (Millions $) |
-13 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Evaxion Biotech A is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer and infectious diseases. The company utilizes artificial intelligence (AI) and machine learning (ML) technologies to design personalized vaccines, tailored to each patient's specific immune response. Their technology platform, known as AI-based Immune-Informatics, analyzes complex genomic data to identify unique antigen targets and predict potential immune responses.
Evaxion Biotech A's vaccines aim to activate the patient's immune system to recognize and destroy cancer cells or neutralize infectious agents. By leveraging AI and ML, the company aims to improve the accuracy and efficiency of vaccine development, resulting in more effective treatments.
The company is also involved in collaborations with academic institutions and pharma companies to advance its research and development initiatives. They are committed to pushing the boundaries of immunotherapy and AI-based vaccine design to improve patient outcomes and contribute to the field of biotechnology.
Company Address: Dr. Neergaards Vej 5F Hørsholm 0
Company Phone Number: 31 24 64 27 Stock Exchange / Ticker: NASDAQ EVAX
|
1.04%